Literature DB >> 27984728

Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules.

Elda Grabocka1, Dafna Bar-Sagi2.   

Abstract

There is growing evidence that stress-coping mechanisms represent tumor cell vulnerabilities that may function as therapeutically beneficial targets. Recent work has delineated an integrated stress adaptation mechanism that is characterized by the formation of cytoplasmic mRNA and protein foci, termed stress granules (SGs). Here, we demonstrate that SGs are markedly elevated in mutant KRAS cells following exposure to stress-inducing stimuli. The upregulation of SGs by mutant KRAS is dependent on the production of the signaling lipid molecule 15-deoxy-delta 12,14 prostaglandin J2 (15-d-PGJ2) and confers cytoprotection against stress stimuli and chemotherapeutic agents. The secretion of 15-d-PGJ2 by mutant KRAS cells is sufficient to enhance SG formation and stress resistance in cancer cells that are wild-type for KRAS. Our findings identify a mutant KRAS-dependent cell non-autonomous mechanism that may afford the establishment of a stress-resistant niche that encompasses different tumor subclones. These results should inform the design of strategies to eradicate tumor cell communities.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  KRAS; cancer; prostaglandins; stress granules

Mesh:

Substances:

Year:  2016        PMID: 27984728      PMCID: PMC5441683          DOI: 10.1016/j.cell.2016.11.035

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  60 in total

1.  TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor.

Authors:  Colleen M Dewey; Basar Cenik; Chantelle F Sephton; Daniel R Dries; Paul Mayer; Shannon K Good; Brett A Johnson; Joachim Herz; Gang Yu
Journal:  Mol Cell Biol       Date:  2010-12-20       Impact factor: 4.272

2.  Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

Authors:  Martin J Edelman; Ming T Tan; Mary J Fidler; Rachel E Sanborn; Greg Otterson; Lecia V Sequist; Tracey L Evans; Bryan J Schneider; Roger Keresztes; John S Rogers; Jorge Antunez de Mayolo; Josephine Feliciano; Yang Yang; Michelle Medeiros; Sara L Zaknoen
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

3.  Sequestration of TRAF2 into stress granules interrupts tumor necrosis factor signaling under stress conditions.

Authors:  Woo Jae Kim; Sung Hoon Back; Vit Kim; Incheol Ryu; Sung Key Jang
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

4.  Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.

Authors:  K Perez; R Walsh; K Brilliant; L Noble; E Yakirevich; V Breese; C Jackson; D Chatterjee; V Pricolo; L Roth; N Shah; T Cataldo; H Safran; D Hixson; P Quesenberry
Journal:  Exp Mol Pathol       Date:  2013-03-22       Impact factor: 3.362

5.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

Authors:  S Shirasawa; M Furuse; N Yokoyama; T Sasazuki
Journal:  Science       Date:  1993-04-02       Impact factor: 47.728

6.  Non-oncogene addiction and the stress phenotype of cancer cells.

Authors:  Nicole L Solimini; Ji Luo; Stephen J Elledge
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

7.  Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.

Authors:  R Rosell; J L González-Larriba; V Alberola; F Molina; M Monzó; D Benito; J M Pérez; J M de Anta
Journal:  Semin Oncol       Date:  1995-12       Impact factor: 4.929

Review 8.  Eukaryotic stress granules: the ins and outs of translation.

Authors:  J Ross Buchan; Roy Parker
Journal:  Mol Cell       Date:  2009-12-25       Impact factor: 17.970

9.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

10.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544

View more
  57 in total

1.  Serine/Arginine-Rich Splicing Factor 3 Modulates the Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2.

Authors:  James T DeLigio; Shaun C Stevens; Gina S Nazario-Muñoz; H Patrick MacKnight; Keli K Doe; Charles E Chalfant; Margaret A Park
Journal:  Mol Cancer Res       Date:  2019-05-28       Impact factor: 5.852

Review 2.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

3.  Stress granule formation, disassembly, and composition are regulated by alphavirus ADP-ribosylhydrolase activity.

Authors:  Aravinth Kumar Jayabalan; Srivathsan Adivarahan; Aakash Koppula; Rachy Abraham; Mona Batish; Daniel Zenklusen; Diane E Griffin; Anthony K L Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

4.  Oncogenes: Coping with stress.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

5.  The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He; Lieven Thorrez; Geraldine Siegfried; Sandra Meulemans; Serge Evrard; Sabine Tejpar
Journal:  Oncogene       Date:  2020-03-06       Impact factor: 9.867

6.  Gle1 mediates stress granule-dependent survival during chemotoxic stress.

Authors:  Laura Glass; Susan R Wente
Journal:  Adv Biol Regul       Date:  2018-09-18

Review 7.  The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway.

Authors:  Liam Baird; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2020-06-15       Impact factor: 4.272

8.  Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.

Authors:  Suman Mukhopadhyay; Debanjan Goswami; Pavan P Adiseshaiah; William Burgan; Ming Yi; Theresa M Guerin; Serguei V Kozlov; Dwight V Nissley; Frank McCormick
Journal:  Cancer Res       Date:  2020-01-07       Impact factor: 12.701

9.  Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autoimmunity.

Authors:  Jiang Dai; Yi-Jiao Huang; Xinhua He; Ming Zhao; Xinzheng Wang; Zhao-Shan Liu; Wen Xue; Hong Cai; Xiao-Yan Zhan; Shao-Yi Huang; Kun He; Hongxia Wang; Na Wang; Zhihong Sang; Tingting Li; Qiu-Ying Han; Jie Mao; Xinwei Diao; Nan Song; Yuan Chen; Wei-Hua Li; Jiang-Hong Man; Ai-Ling Li; Tao Zhou; Zheng-Gang Liu; Xue-Min Zhang; Tao Li
Journal:  Cell       Date:  2019-02-21       Impact factor: 41.582

Review 10.  Stress Granules and Processing Bodies in Translational Control.

Authors:  Pavel Ivanov; Nancy Kedersha; Paul Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-05-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.